THOUSAND OAKS, Calif., Aug. 25, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has broadened the approved use of Repatha ® (evolocumab) to ...

The FDA has expanded the approval of Repatha to reduce the risk of major adverse cardiovascular events in adults at increased risk for these events.

Repatha (evolocumab) is an injectable medicine that helps lower levels of low-density lipoprotein cholesterol (LDL), often called “bad” cholesterol. Approved in 2015, Repatha can now be used in adults ...

Amgen recently received an expanded FDA approval for Repatha®, broadening its use for adults at risk of major cardiovascular events. During the same quarter, the company reported significant earnings ...

Cost watchdog the National Institute for Health and Care Excellence has turned down Amgen’s Repatha - the world’s first approved PCSK9 inhibitor - as an option for people with high cholesterol and ...